Clinical trials: BRAF V600 Mutation
Non Small Cell Lung Cancer, BRAF V600 Mutation
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
BLaDE cohort will evaluate overall survival (OS), real world progression-free survival (PFS), best response and duration of treatment in patients with advanced, metastatic Non-Small Cell Lung Cancer (NSCLC) harboring BRAF V600E…
- Trial name
- BLaDE (NCT04775095)
- Where
- 2 sites in France
- Volunteers
- 163 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Metastatic Melanoma (Carrying BRAF V600 Mutation)
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
The BRAF inhibitors dabrafenib and vemurafenib belong both two a new class of potent anti-cancer drugs and are highly efficacious in tumors harboring the BRAF V600E mutation.
- Trial name
- NCT02052193
- Testing
- Dabrafenib, Vemurafenib
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- University Hospital Tuebingen
Melanoma Metastatic, BRAF V600 Mutation
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.
The purpose of this study is to evaluate the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive…
- Trial name
- NCT03514901
- Testing
- Experimental combination beyond Focal Progression, Pembrolizumab or Nivolumab
- Where
- 14 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Intergruppo Melanoma Italiano
Melanoma, BRAF V600 Mutation
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05103891
- Testing
- Binimetinib Oral Tablet
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Cutaneous Melanoma, Stage IV, BRAF V600 Mutation
Advanced Melanoma in Russian Experience
Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation
- Trial name
- ADMIRE (NCT03663647)
- Where
- 11 sites in Russia
- Volunteers
- 382 people
- Sponsor
- MelanomaPRO, Russia
Metastatic Melanoma, BRAF V600 Mutation Positive
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing…
- Trial name
- NCT02608034
- Testing
- Itraconazole, Rifampin, Vemurafenib
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 32 people
- Sponsor
- Genentech, Inc.